Back to YC Companies
Engage Bio
Winter 2022
Acquired
Potent, durable, and redosable non-viral genetic medicines
10 people View on YC
Engage Bio at a glance
- Y Combinator batch
- Winter 2022
- Status
- Acquired
- Industry
- Healthcare
- Team size
- 10 people
- Location
- Not recorded
- Website
- Not recorded
Every field above comes from the Y Combinator company record. Nothing is estimated.
About Engage Bio
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
Tags:
Synthetic Biology
Biotech
Healthcare
Therapeutics
Drug discovery